Clinical observations with pizotifene (Sandomigran) in the treatment of nonmigrainous depressed women.
Based on earlier clinical experiences a group of 52 nonmigrainous depressed women were treated with 3-6 mh/day pizotifene (Sandomigran-Sandoz) in order to evaluate a presumed antidepressant action. The Bunney-Hamburg behavior-rating scale was employed to quantify the results. Thirteen patients showed marked improvement and 22 patients partial improvement after three weeks' treatment. Involutional and psychoreactive depressions responded better than endogenous forms. Symptomatically, anxiety and dysphoria were significantly more favorably influenced than retardation or paranoia. No serious side effects were observed.
D000328:Adult; D000341:Affective Disorders, Psychotic / Q000188:drug therapy; D001007:Anxiety / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D010259:Paranoid Disorders / Q000188:drug therapy; D010918:Pizotyline / Q000008:administration & dosage / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*
D013876:Thiophenes; D010918:Pizotyline